Clinical Trial Update: Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta [Phase 3]

View source ↗

Summary

Phase 3 pediatric safety follow-up study evaluating prior romosozumab treatment in Osteogenesis Imperfecta is currently recruiting. The sponsor is Amgen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• Evenity (romosozumab)

Snippet

Sponsor: Amgen | Conditions: Osteogenesis Imperfecta | Phase 3 | Status: RECRUITING